Fudan University
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private
- Established
- 1905-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.fudan.edu.cn
ALPPS Combined With Tislelizumab in Liver Malignancy
- First Posted Date
- 2021-08-09
- Last Posted Date
- 2021-08-09
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 20
- Registration Number
- NCT04996446
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
Long-term Survivorship of Discharged Patients With Malignant Tumor Based on Single-institutional Cancer Registry
Recruiting
- Conditions
- SurvivalSurgeryRadiotherapyDrug TherapyNeoplasms
- Interventions
- Procedure: hospitalization
- First Posted Date
- 2021-08-09
- Last Posted Date
- 2021-08-09
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 500000
- Registration Number
- NCT04996732
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
Induction Chemotherapy and Toripalimab for Larynx Preservation in Resectable Laryngeal/Hypopharyngeal Carcinoma
Phase 2
Recruiting
- Conditions
- Laryngeal CancerHypopharynx CancerLaryngeal Neoplasms
- Interventions
- Drug: chemotherapy TP regimen combined with Toripalimab
- First Posted Date
- 2021-08-06
- Last Posted Date
- 2022-01-18
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 42
- Registration Number
- NCT04995120
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Prediction of 18F-FES-PET/CT Parameters on Palbociclib Combined With ET
- First Posted Date
- 2021-08-05
- Last Posted Date
- 2022-05-19
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 50
- Registration Number
- NCT04992156
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab in Unresectable Biliary Tract Cancer
Phase 2
Active, not recruiting
- Conditions
- Biliary Tract CarcinomaInitially Unresectable
- Interventions
- Drug: Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab
- First Posted Date
- 2021-08-02
- Last Posted Date
- 2023-01-26
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 37
- Registration Number
- NCT04984980
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
Research on Risk Factors and Interventions of Polycystic Ovary Syndrome Complicated With Depression and Anxiety
Not Applicable
Recruiting
- Conditions
- PCOS (Polycystic Ovary Syndrome) of Bilateral OvariesDepression, Anxiety
- Interventions
- First Posted Date
- 2021-07-30
- Last Posted Date
- 2022-10-05
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 100
- Registration Number
- NCT04984070
- Locations
- 🇨🇳
OB & GYN Hospital of Fudan University, Shanghai, Shanghai, China
Effect of a Probiotic Strain Lactobacillus Paracasei K56 on Metabolic Symptom - a Pilot Study
Not Applicable
Completed
- Conditions
- ObesityAdiposity
- Interventions
- Dietary Supplement: probiotic capsule E10Dietary Supplement: probiotic drink with Lactobacillus paracasei K56Dietary Supplement: probiotic capsule E11Dietary Supplement: probiotic capsule E9Dietary Supplement: maltodextrinDietary Supplement: Probiotic powder E3Dietary Supplement: Probiotic powder E5Dietary Supplement: probiotic capsule E7
- First Posted Date
- 2021-07-28
- Last Posted Date
- 2023-01-10
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 118
- Registration Number
- NCT04980599
- Locations
- 🇨🇳
Hua Dong Hospital Affiliated to Fu Dan University, Shanghai, China
GEMOX Combined With Donafenib and Tislelizumab in Biliary Tract Cancer
Phase 1
- Conditions
- Biliary Tract Carcinoma
- Interventions
- Combination Product: Combination of Gemcitabine, Oxaliplatin, Donafenib and Tislelizumab
- First Posted Date
- 2021-07-28
- Last Posted Date
- 2021-08-09
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 10
- Registration Number
- NCT04979663
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
Fluzoparib and Camrelizumab in Treating Patients With R/M NPC That Progressed After First-line Chemotherapy
Phase 2
Recruiting
- Conditions
- Nasopharyngeal CarcinomaNasopharyngeal Cancer
- Interventions
- First Posted Date
- 2021-07-27
- Last Posted Date
- 2022-06-07
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 48
- Registration Number
- NCT04978012
- Locations
- 🇨🇳
Fudan Universtiy Shanghai Cancer Centre, Shanghai, Shanghai, China
PD-1 Antibody and Lenvatinib Plus TACE on Downstaging BCLC B/C HCC
Early Phase 1
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Combination Product: PD-1 and Lenvatinib Plus TACE
- First Posted Date
- 2021-07-23
- Last Posted Date
- 2022-08-18
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 50
- Registration Number
- NCT04974281
- Locations
- 🇨🇳
Huashan hospital, Shanghai, Shanghai, China
© Copyright 2025. All Rights Reserved by MedPath